Search
Menu
Home
HTB
2022
April
April 2022
Contents
Editorial
HTB April 2022 (1 April 2022)
Conference reports
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
CROI 2022: Webcasts now online and open access
CROI 2022: Islatravir studies for HIV treatment and PrEP
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
CROI 2022: UK study shows PEP is started earlier using home starter packs
CROI 2022: Summary of 14 key studies on HIV and liver disease
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
Antiretrovirals
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents
HIV prevention and transmission
HIV vaccine study using mRNA technology starts in the US
South Africa approves dapivirine vaginal ring for HIV prevention
COVID-19: HIV and COVID-19 coinfection
BHIVA statement on fourth vaccine dose for people living with HIV in the UK
COVID-19: vaccine research
Temporary protection against omicron needs mRNA booster: limited data for those at highest risk
PDFs
HTB: no. 4 (1 April 2022) PDF downloads
HTB RSS
Early access
Mpox vaccine efficacy dramatically lower in people living with HIV
26 March 2025
All early access reports
Current issues
March 2025
February 2025
January 2025
Back issues
Special report
CROI 2025: BHIVA best of CROI feedback meeting
28 March 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate